Hubbry Logo
HyperthyroidismHyperthyroidismMain
Open search
Hyperthyroidism
Community hub
Hyperthyroidism
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Hyperthyroidism
Hyperthyroidism
from Wikipedia

Hyperthyroidism
Other namesOveractive thyroid, hyperthyreosis
Triiodothyronine (T3, pictured) and thyroxine (T4) are both forms of thyroid hormone.
SpecialtyEndocrinology
SymptomsIrritability, muscle weakness, sleeping problems, fast heartbeat, heat intolerance, diarrhea, enlargement of the thyroid, weight loss[1]
ComplicationsThyroid storm[2]
Usual onset20–50 years old[2]
CausesGraves' disease, multinodular goiter, toxic adenoma, inflammation of the thyroid, eating too much iodine, too much synthetic thyroid hormone[1][2]
Diagnostic methodBased on symptoms and confirmed by blood tests[1]
TreatmentRadioiodine therapy, medications, thyroid surgery[1]
MedicationBeta blockers, methimazole[1]
Frequency1.2% (US)[3]
DeathsRare directly, unless thyroid storm occurs; associated with increased mortality if untreated (1.23 HR)[4]

Hyperthyroidism is a endocrine disease in which the thyroid gland produces excessive amounts of thyroid hormones.[3] Thyrotoxicosis is a condition that occurs due to elevated levels of thyroid hormones of any cause and therefore includes hyperthyroidism.[3] Some, however, use the terms interchangeably.[5] Signs and symptoms vary between people and may include irritability, muscle weakness, sleeping problems, a fast heartbeat, heat intolerance, diarrhea, enlargement of the thyroid, hand tremor, and weight loss.[1] Symptoms are typically less severe in the elderly and during pregnancy.[1] An uncommon but life-threatening complication is thyroid storm in which an event such as an infection results in worsening symptoms such as confusion and a high temperature; this often results in death.[2] The opposite is hypothyroidism, when the thyroid gland does not make enough thyroid hormone.[6]

Graves' disease is the cause of about 50% to 80% of the cases of hyperthyroidism in the United States.[1][7] Other causes include multinodular goiter, toxic adenoma, inflammation of the thyroid, eating too much iodine, and too much synthetic thyroid hormone.[1][2] A less common cause is a pituitary adenoma.[1] The diagnosis may be suspected based on signs and symptoms and then confirmed with blood tests.[1] Typically blood tests show a low thyroid stimulating hormone (TSH) and raised T3 or T4.[1] Radioiodine uptake by the thyroid, thyroid scan, and measurement of antithyroid autoantibodies (thyroidal thyrotropin receptor antibodies are positive in Graves' disease) may help determine the cause.[1]

Treatment depends partly on the cause and severity of the disease.[1] There are three main treatment options: radioiodine therapy, medications, and thyroid surgery.[1] Radioiodine therapy involves taking iodine-131 by mouth, which is then concentrated in and destroys the thyroid over weeks to months.[1] The resulting hypothyroidism is treated with synthetic thyroid hormone.[1] Medications such as beta blockers may control the symptoms, and anti-thyroid medications such as methimazole may temporarily help people while other treatments are having an effect.[1] Surgery to remove the thyroid is another option.[1] This may be used in those with very large thyroids or when cancer is a concern.[1] In the United States, hyperthyroidism affects about 1.2% of the population.[3] Worldwide, hyperthyroidism affects 2.5% of adults.[8] It occurs between two and ten times more often in women.[1] Onset is commonly between 20 and 50 years of age.[2] Overall, the disease is more common in those over the age of 60 years.[1]

Signs and symptoms

[edit]

Hyperthyroidism may be asymptomatic or present with significant symptoms.[2] Some of the symptoms of hyperthyroidism include nervousness, irritability, increased perspiration, heart racing, hand tremors, anxiety, trouble sleeping, thinning of the skin, fine brittle hair, and muscular weakness—especially in the upper arms and thighs. More frequent bowel movements may occur, and diarrhea is common. Weight loss, sometimes significant, may occur despite a good appetite (though 10% of people with a hyperactive thyroid experience weight gain), vomiting may occur, and, for women, menstrual flow may lighten and menstrual periods may occur less often, or with longer cycles than usual.[9][10]

Exophthalmos seen in Graves' ophthalmopathy

The thyroid hormone is critical to the normal function of cells. In excess, it both overstimulates metabolism and disrupts the normal functioning of sympathetic nervous system, causing speeding up of various body systems and symptoms resembling an overdose of epinephrine (adrenaline). These include fast heartbeat and symptoms of palpitations, nervous system tremor such as of the hands and anxiety symptoms, digestive system hypermotility, unintended weight loss, and, in lipid panel blood tests, a lower and sometimes unusually low serum cholesterol.[11]

Major clinical signs of hyperthyroidism include weight loss (often accompanied by an increased appetite), anxiety, heat intolerance, hair loss, muscle aches, weakness, fatigue, hyperactivity, irritability, high blood sugar,[11] excessive urination, excessive thirst, delirium, tremor, pretibial myxedema (in Graves' disease), emotional lability, and sweating. Panic attacks, inability to concentrate, and memory problems may also occur. Psychosis and paranoia, common during thyroid storm, are rare with milder hyperthyroidism. Many persons will experience complete remission of symptoms 1 to 2 months after a euthyroid state is obtained, with a marked reduction in anxiety, sense of exhaustion, irritability, and depression. Some individuals may have an increased rate of anxiety or persistence of affective and cognitive symptoms for several months to up to 10 years after a euthyroid state is established.[12] In addition, those with hyperthyroidism may present with a variety of physical symptoms such as palpitations and abnormal heart rhythms (the notable ones being atrial fibrillation), shortness of breath (dyspnea), loss of libido, amenorrhea, nausea, vomiting, diarrhea, gynecomastia and feminization.[13] Long term untreated hyperthyroidism can lead to osteoporosis. These classical symptoms may not be present often in the elderly.[14]

Bone loss, which is associated with overt but not subclinical hyperthyroidism, may occur in 10 to 20% of patients. This may be due to an increase in bone remodelling and a decrease in bone density, which increases fracture risk. It is more common in postmenopausal women; less so in younger women and men. Bone disease related to hyperthyroidism was first described by Frederick von Recklinghausen, in 1891; he described the bones of a woman who died of hyperthyroidism as appearing "worm-eaten".[15]

Neurological manifestations can include tremors, chorea, myopathy, and in some susceptible individuals (in particular of Asian descent) periodic paralysis. An association between thyroid disease and myasthenia gravis has been recognized. Thyroid disease, in this condition, is autoimmune in nature, and approximately 5% of people with myasthenia gravis also have hyperthyroidism. Myasthenia gravis rarely improves after thyroid treatment and the relationship between the two entities is becoming better understood over the past 15 years.[16][17][18]

Illustration depicting enlarged thyroid that may be associated with hyperthyroidism

In Graves' disease, ophthalmopathy may cause the eyes to look enlarged because the eye muscles swell and push the eye forward. Sometimes, one or both eyes may bulge. Some have swelling of the front of the neck from an enlarged thyroid gland (a goiter).[19]

Minor ocular (eye) signs, which may be present in any type of hyperthyroidism, are eyelid retraction ("stare"), extraocular muscle weakness, and lid-lag.[20] In hyperthyroid stare (Dalrymple sign) the eyelids are retracted upward more than normal (the normal position is at the superior corneoscleral limbus, where the "white" of the eye begins at the upper border of the iris). Extraocular muscle weakness may present with double vision. In lid-lag (von Graefe's sign), when the person tracks an object downward with their eyes, the eyelid fails to follow the downward-moving iris, and the same type of upper globe exposure which is seen with lid retraction occurs, temporarily. These signs disappear with treatment of the hyperthyroidism.[citation needed]

Neither of these ocular signs should be confused with exophthalmos (protrusion of the eyeball), which occurs specifically and uniquely in hyperthyroidism caused by Graves' disease (note that not all exophthalmos is caused by Graves' disease, but when present with hyperthyroidism is diagnostic of Graves' disease). This forward protrusion of the eyes is due to immune-mediated inflammation in the retro-orbital (eye socket) fat. Exophthalmos, when present, may exacerbate hyperthyroid lid-lag and stare.[21]

Thyroid storm

[edit]

Thyroid storm is a severe form of thyrotoxicosis characterized by rapid and often irregular heartbeat, high temperature, vomiting, diarrhea, and mental agitation. Symptoms may not be typical in the young, old, or pregnant.[2] It usually occurs due to untreated hyperthyroidism and can be provoked by infections.[2] It is a medical emergency and requires hospital care to control the symptoms rapidly. The mortality rate in thyroid storm is 3.6-17%, usually due to multi-organ system failure.[8]

Hypothyroidism

[edit]

Hyperthyroidism due to certain types of thyroiditis can eventually lead to hypothyroidism (a lack of thyroid hormone), as the thyroid gland is damaged. Also, radioiodine treatment of Graves' disease often eventually leads to hypothyroidism. Such hypothyroidism may be diagnosed with thyroid hormone testing and treated by oral thyroid hormone supplementation.[22]

Causes

[edit]
Most common causes of hyperthyroidism by age.[23]

There are several causes of hyperthyroidism. Most often, the entire gland is overproducing thyroid hormone. Less commonly, a single nodule is responsible for the excess hormone secretion, called a "hot" nodule. Thyroiditis (inflammation of the thyroid) can also cause hyperthyroidism.[24] Functional thyroid tissue producing an excess of thyroid hormone occurs in a number of clinical conditions.

The major causes in humans are:

  • Graves' disease. An autoimmune disease (usually, the most common cause with 50–80% worldwide, although this varies substantially with location- i.e., 47% in Switzerland (Horst et al., 1987) to 90% in the USA (Hamburger et al. 1981)). Thought to be due to varying levels of iodine in the diet.[25] It is eight times more common in females than males and often occurs in young females, around 20 to 40 years of age.[26]
  • Toxic thyroid adenoma (the most common cause in Switzerland, 53%, thought to be atypical due to a low level of dietary iodine in this country)[25]
  • Toxic multinodular goiter[citation needed]

High blood levels of thyroid hormones (most accurately termed hyperthyroxinemia) can occur for several other reasons:

  • Inflammation of the thyroid is called thyroiditis. There are several different kinds of thyroiditis, including Hashimoto's thyroiditis (Hypothyroidism immune-mediated), and subacute thyroiditis (de Quervain's). These may be initially associated with secretion of excess thyroid hormone but usually progress to gland dysfunction and, thus, to hormone deficiency and hypothyroidism.
  • Oral consumption of excess thyroid hormone tablets is possible (surreptitious use of thyroid hormone), as is the rare event of eating ground beef or pork contaminated with thyroid tissue, and thus thyroid hormones (termed hamburger thyrotoxicosis or alimentary thyrotoxicosis).[27] Pharmacy compounding errors may also be a cause.[28]
  • Amiodarone, an antiarrhythmic drug, is structurally similar to thyroxine and may cause either under-or overactivity of the thyroid.[citation needed]
  • Postpartum thyroiditis (PPT) occurs in about 7% of women during the year after they give birth. PPT typically has several phases, the first of which is hyperthyroidism. This form of hyperthyroidism usually corrects itself within weeks or months without the need for treatment.
  • A struma ovarii is a rare form of monodermal teratoma that contains mostly thyroid tissue, which leads to hyperthyroidism.
  • Excess iodine consumption, notably from algae such as kelp.

Thyrotoxicosis can also occur after taking too much thyroid hormone in the form of supplements, such as levothyroxine (a phenomenon known as exogenous thyrotoxicosis, alimentary thyrotoxicosis, or occult factitial thyrotoxicosis).[29]

Hypersecretion of thyroid stimulating hormone (TSH), which in turn is almost always caused by a pituitary adenoma, accounts for much less than 1 percent of hyperthyroidism cases.[30]

Diagnosis

[edit]

Measuring the level of thyroid-stimulating hormone (TSH), produced by the pituitary gland (which in turn is also regulated by the hypothalamus's TSH-Releasing Hormone) in the blood, is typically the initial test for suspected hyperthyroidism. A low TSH level typically indicates that the pituitary gland is being inhibited or "instructed" by the brain to cut back on stimulating the thyroid gland, having sensed increased levels of T4 and/or T3 in the blood. In rare circumstances, a low TSH indicates primary failure of the pituitary, or temporary inhibition of the pituitary due to another illness (euthyroid sick syndrome) and so checking the T4 and T3 is still clinically useful.[11]

Measuring specific antibodies, such as anti-TSH-receptor antibodies in Graves' disease, or anti-thyroid peroxidase in Hashimoto's thyroiditis—a common cause of hypothyroidism—may also contribute to the diagnosis. The diagnosis of hyperthyroidism is confirmed by blood tests that show a decreased thyroid-stimulating hormone (TSH) level and elevated T4 and T3 levels. TSH is a hormone made by the pituitary gland in the brain that tells the thyroid gland how much hormone to make. When there is too much thyroid hormone, the TSH will be low. A radioactive iodine uptake test and thyroid scan together characterize or enable radiologists and doctors to determine the cause of hyperthyroidism. The uptake test uses radioactive iodine injected or taken orally on an empty stomach to measure the amount of iodine absorbed by the thyroid gland. People with hyperthyroidism absorb much more iodine than healthy people, including radioactive iodine, which is easy to measure. A thyroid scan producing images is typically conducted in connection with the uptake test to allow visual examination of the over-functioning gland.[11]

Thyroid scintigraphy is a useful test to characterize (distinguish between causes of) hyperthyroidism, and this entity from thyroiditis. This test procedure typically involves two tests performed in connection with each other: an iodine uptake test and a scan (imaging) with a gamma camera. The uptake test involves administering a dose of radioactive iodine (radioiodine), traditionally iodine-131 (131I), and more recently iodine-123 (123I). Iodine-123 may be the preferred radionuclide in some clinics due to its more favorable radiation dosimetry (i.e., less radiation dose to the person per unit administered radioactivity) and a gamma photon energy more amenable to imaging with the gamma camera. For the imaging scan, I-123 is considered an almost ideal isotope of iodine for imaging thyroid tissue and thyroid cancer metastasis.[31] Thyroid scintigraphy should not be performed in those who are pregnant, a thyroid ultrasound with color flow doppler may be obtained as an alternative in these circumstances.[8]

Typical administration involves a pill or liquid containing sodium iodide (NaI) taken orally, which contains a small amount of iodine-131, amounting to perhaps less than a grain of salt. A 2-hour fast of no food prior to and for 1 hour after ingesting the pill is required. This low dose of radioiodine is typically tolerated by individuals otherwise allergic to iodine (such as those unable to tolerate contrast mediums containing larger doses of iodine such as used in CT scan, intravenous pyelogram (IVP), and similar imaging diagnostic procedures). Excess radioiodine that does not get absorbed into the thyroid gland is eliminated by the body in urine. Some people with hyperthyroidism may experience a slight allergic reaction to the diagnostic radioiodine and may be given an antihistamine.[citation needed]

The person returns 24 hours later to have the level of radioiodine "uptake" (absorbed by the thyroid gland) measured by a device with a metal bar placed against the neck, which measures the radioactivity emitted from the thyroid. This test takes about 4 minutes while the uptake % (i.e., percentage) is accumulated (calculated) by the machine software. A scan is also performed, wherein images (typically a center, left, and right angle) are taken of the contrasted thyroid gland with a gamma camera; a radiologist will read and prepare a report indicating the uptake % and comments after examining the images. People with hyperthyroidism will typically "take up" higher-than-normal levels of radioiodine. Normal ranges for RAI uptake are from 10 to 30%.

In addition to testing the TSH levels, many doctors test for T3, Free T3, T4, and/or Free T4 for more detailed results. Free T4 is unbound to any protein in the blood. Adult limits for these hormones are: TSH (units): 0.45 – 4.50 uIU/mL; T4 Free/Direct (nanograms): 0.82 – 1.77 ng/dl; and T3 (nanograms): 71 – 180 ng/dl. Persons with hyperthyroidism can easily exhibit levels many times these upper limits for T4 and/or T3. See a complete table of normal range limits for thyroid function at the thyroid gland article.

In hyperthyroidism, CK-MB (Creatine kinase) is usually elevated.[32]

Subclinical

[edit]

In overt primary hyperthyroidism, TSH levels are low, and T4 and T3 levels are high. Subclinical hyperthyroidism is a milder form of hyperthyroidism characterized by low or undetectable serum TSH level, but with a normal serum free thyroxine level.[33] Although the evidence for doing so is not definitive, treatment of elderly persons having subclinical hyperthyroidism could reduce the number of cases of atrial fibrillation.[34] There is also an increased risk of bone fractures (by 42%) in people with subclinical hyperthyroidism; there is insufficient evidence to say whether treatment with antithyroid medications would reduce that risk.[35]

A 2022 meta-analysis found subclinical hyperthyroidism to be associated with cardiovascular death.[36]

Screening

[edit]

In those without symptoms who are not pregnant, there is little evidence for or against screening.[37]

Treatment

[edit]

Antithyroid drugs

[edit]

Thyrostatics (antithyroid drugs) are drugs that inhibit the production of thyroid hormones, such as carbimazole (used in the UK) and methimazole (used in the US, Germany, and Russia), and propylthiouracil. Thyrostatics are believed to work by inhibiting the iodination of thyroglobulin by thyroperoxidase and, thus, the formation of tetraiodothyronine (T4). Propylthiouracil also works outside the thyroid gland, preventing the conversion of (mostly inactive) T4 to the active form T3. Because thyroid tissue usually contains a substantial reserve of thyroid hormone, thyrostatics can take weeks to become effective, and the dose often needs to be carefully titrated over a period of months, with regular doctor visits and blood tests to monitor results.[11]

Beta-blockers

[edit]

Many of the common symptoms of hyperthyroidism, such as palpitations, trembling, and anxiety, are mediated by increases in beta-adrenergic receptors on cell surfaces. Beta blockers, typically used to treat high blood pressure, are a class of drugs that offset this effect, reducing rapid pulse associated with the sensation of palpitations, and decreasing tremor and anxiety. Thus, a person with hyperthyroidism can often obtain immediate temporary relief until the hyperthyroidism can be characterized with the Radioiodine test noted above, and more permanent treatment takes place. Note that these drugs do not treat hyperthyroidism or any of its long-term effects if left untreated, but rather, they treat or reduce only symptoms of the condition.[38]

Some minimal effect on thyroid hormone production, however, also comes with propranolol, which has two roles in the treatment of hyperthyroidism, determined by the different isomers of propranolol. L-propranolol causes beta-blockade, thus treating the symptoms associated with hyperthyroidism, such as tremor, palpitations, anxiety, and heat intolerance. D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T4 to T3, providing some, though minimal, therapeutic effect. Other beta-blockers are used to treat only the symptoms associated with hyperthyroidism.[39] Propranolol in the UK, and metoprolol in the US, are most frequently used to augment treatment for people with hyperthyroid.[40]

Diet

[edit]

People with autoimmune hyperthyroidism (such as in Graves' disease) should not eat foods high in iodine, such as edible seaweed and seafood.[1]

From a public health perspective, the general introduction of iodized salt in the United States in 1924 resulted in lower disease, goiters, as well as improving the lives of children whose mothers would not have eaten enough iodine during pregnancy, which would have lowered the IQs of their children.[41]

Surgery

[edit]

Surgery (thyroidectomy to remove the whole thyroid or a part of it) is not extensively used because most common forms of hyperthyroidism are quite effectively treated by the radioactive iodine method, and because there is a risk of also removing the parathyroid glands, and of cutting the recurrent laryngeal nerve, making swallowing difficult, and even simply generalized staphylococcal infection as with any major surgery. Some people with Graves' may opt for surgical intervention. This includes those who cannot tolerate medicines for one reason or another, people who are allergic to iodine, or people who refuse radioiodine.[42]

A 2019 systematic review concluded that the available evidence shows no difference between visually identifying the nerve or utilizing intraoperative neuroimaging during surgery, when trying to prevent injury to the recurrent laryngeal nerve during thyroid surgery.[43]

If people have toxic nodules, treatments typically include either the removal or injection of the nodule with alcohol.[44]

Radioiodine

[edit]

In iodine-131 (radioiodine) radioisotope therapy, which was first pioneered by Dr. Saul Hertz,[45] radioactive iodine-131 is given orally (either by pill or liquid) on a one-time basis, to severely restrict, or altogether destroy the function of a hyperactive thyroid gland. This isotope of radioactive iodine used for ablative treatment is more potent than diagnostic radioiodine (usually iodine-123 or a very low amount of iodine-131), which has a biological half-life from 8–13 hours. Iodine-131, which also emits beta particles that are far more damaging to tissues at short range, has a half-life of approximately 8 days. People not responding sufficiently to the first dose are sometimes given an additional radioiodine treatment, at a larger dose. Iodine-131 in this treatment is picked up by the active cells in the thyroid and destroys them, rendering the thyroid gland mostly or completely inactive.[46]

Since iodine is picked up more readily (though not exclusively) by thyroid cells, and (more importantly) is picked up even more readily by overactive thyroid cells, the destruction is local, and there are no widespread side effects with this therapy. Radioiodine ablation has been used for over 50 years, and the only major reasons for not using it are pregnancy and breastfeeding (breast tissue also picks up and concentrates iodine). Once the thyroid function is reduced, replacement hormone therapy (levothyroxine) taken orally each day replaces the thyroid hormone that is normally produced by the body.[47]

There is extensive experience, over many years, of the use of radioiodine in the treatment of thyroid overactivity, and this experience does not indicate any increased risk of thyroid cancer following treatment. However, a study from 2007 has reported an increased number of cancer cases after radioiodine treatment for hyperthyroidism.[46]

The principal advantage of radioiodine treatment for hyperthyroidism is that it tends to have a much higher success rate than medications. Depending on the dose of radioiodine chosen, and the disease under treatment (Graves' vs. toxic goiter, vs. hot nodule, etc.), the success rate in achieving definitive resolution of the hyperthyroidism may vary from 75 to 100%. A major expected side-effect of radioiodine in people with Graves' disease is the development of lifelong hypothyroidism, requiring daily treatment with thyroid hormone. On occasion, some people may require more than one radioactive treatment, depending on the type of disease present, the size of the thyroid, and the initial dose administered.[48]

People with Graves' disease manifesting moderate or severe Graves' ophthalmopathy are cautioned against radioactive iodine-131 treatment, since it has been shown to exacerbate existing thyroid eye disease. People with mild or no ophthalmic symptoms can mitigate their risk with a concurrent six-week course of prednisone. The mechanisms proposed for this side effect involve a TSH receptor common to both thyrocytes and retro-orbital tissue.[49]

As radioactive iodine treatment results in the destruction of thyroid tissue, there is often a transient period of several days to weeks when the symptoms of hyperthyroidism may worsen following radioactive iodine therapy. In general, this happens as a result of thyroid hormones being released into the blood following the radioactive iodine-mediated destruction of thyroid cells that contain thyroid hormone. In some people, treatment with medications such as beta blockers (propranolol, atenolol, etc.) may be useful during this period. Most people do not experience any difficulty after the radioactive iodine treatment, usually given as a small pill. On occasion, neck tenderness or a sore throat may become apparent after a few days, if moderate inflammation in the thyroid develops and produces discomfort in the neck or throat area. This is usually transient, and not associated with a fever, etc.[citation needed]

It is recommended that breastfeeding be stopped at least six weeks before radioactive iodine treatment and that it not be resumed, although it can be done in future pregnancies. It also shouldn't be done during pregnancy, and pregnancy should be put off until at least 6–12 months after treatment.[50][51]

A common outcome following radioiodine is a swing from hyperthyroidism to easily treatable hypothyroidism, which occurs in 78% of those treated for Graves' thyrotoxicosis and in 40% of those with toxic multinodular goiter or solitary toxic adenoma.[52] Use of higher doses of radioiodine reduces the number of cases of treatment failure, with a penalty for higher response to treatment consisting mostly of higher rates of eventual hypothyroidism, which requires hormone treatment for life.[53]

There is increased sensitivity to radioiodine therapy in thyroids appearing on ultrasound scans as more uniform (hypoechogenic), due to densely packed large cells, with 81% later becoming hypothyroid, compared to just 37% in those with more normal scan appearances (normoechogenic).[54]

Thyroid storm

[edit]

Thyroid storm presents with extreme symptoms of hyperthyroidism. It is treated aggressively with resuscitation measures along with a combination of the above modalities including: intravenous beta blockers such as propranolol, followed by a thioamide such as methimazole, an iodinated radiocontrast agent or an iodine solution if the radiocontrast agent is not available, and an intravenous steroid such as hydrocortisone.[55] Propylthiouracil is the preferred thioamide in thyroid storm as it can prevent the conversion of T4 to the more active T3 in the peripheral tissues in addition to inhibiting thyroid hormone production.[8]

Alternative medicine

[edit]

In countries such as China, herbs used alone or with antithyroid medications are used to treat hyperthyroidism.[56] Very low quality evidence suggests that traditional Chinese herbal medications may be beneficial when taken along with routine hyperthyroid medications, however, there is no reliable evidence to determine the effectiveness of Chinese herbal medications for treating hyperthyroidism.[56]

Epidemiology

[edit]

In the United States, hyperthyroidism affects about 1.2% of the population.[3] About half of these cases have obvious symptoms, while the other half do not.[2] It occurs between two and ten times more often in women.[1] The disease is more common in those over the age of 60 years.[1]

Subclinical hyperthyroidism modestly increases the risk of cognitive impairment and dementia.[57]

History

[edit]

Caleb Hillier Parry first made the association between the goiter and eye protrusion in 1786; however, he did not publish his findings until 1825.[58] In 1835, Irish doctor Robert James Graves discovered a link between the protrusion of the eyes and goiter, giving his name to the autoimmune disease now known as Graves' Disease.[citation needed]

Pregnancy

[edit]

Recognizing and evaluating hyperthyroidism in pregnancy is a diagnostic challenge.[59] Thyroid hormones are commonly elevated during the first trimester of pregnancy as the pregnancy hormone human chorionic gonadotropin (hCG) stimulates thyroid hormone production, in a condition known as gestational transient thyrotoxicosis.[8] Gestational transient thyrotoxicosis generally abates in the second trimester as hCG levels decline and thyroid function normalizes.[8] Hyperthyroidism can increase the risk of complications for mother and child.[60] Such risks include pregnancy-related hypertension, pregnancy loss, low-birth weight, pre-eclampsia, preterm delivery, still birth and behavioral disorders later in the child's life.[8][61][60][62] Nonetheless, high maternal FT4 levels during pregnancy have been associated with impaired brain developmental outcomes of the offspring and this was independent of hCG levels.[63]

Propylthiouracil is the preferred antithyroid medication in the 1st trimester of pregnancy as it is less teratogenic than methimazole.[8]

Other animals

[edit]

Cats

[edit]

Hyperthyroidism is one of the most common endocrine conditions affecting older domesticated housecats. In the United States, up to 10% of cats over ten years old have hyperthyroidism.[64] The disease has become significantly more common since the first reports of feline hyperthyroidism in the 1970s. The most common cause of hyperthyroidism in cats is the presence of benign tumors called adenomas. 98% of cases are caused by the presence of an adenoma,[65] but the reason these cats develop such tumors continues to be studied.

The most common presenting symptoms are: rapid weight loss, tachycardia (rapid heart rate), vomiting, diarrhea, increased consumption of fluids (polydipsia), increased appetite (polyphagia), and increased urine production (polyuria). Other symptoms include hyperactivity, possible aggression, an unkempt appearance, and large, thick claws. Heart murmurs and a gallop rhythm can develop due to secondary hypertrophic cardiomyopathy. About 70% of affected cats also have enlarged thyroid glands (goiter). 10% of cats exhibit "apathetic hyperthyroidism", which is characterized by anorexia and lethargy.[66]

The same three treatments used with humans are also options in treating feline hyperthyroidism (surgery, radioiodine treatment, and anti-thyroid drugs). There is also a special low iodine diet available that will control the symptoms, providing no other food is fed; Hill's y/d formula, when given exclusively, decreases T4 production by limiting the amount of iodine needed for thyroid hormone production. It is the only available commercial diet that focuses on managing feline hyperthyroidism. Medical and dietary management using methimazole and Hill's y/d cat food will give hyperthyroid cats an average of 2 years before dying due to secondary conditions such as heart and kidney failure.[66] Drugs used to help manage the symptoms of hyperthyroidism are methimazole and carbimazole. Drug therapy is the least expensive option, even though the drug must be administered daily for the remainder of the cat's life. Carbimazole is only available as a once-daily tablet. Methimazole is available as an oral solution, a tablet, and compounded as a topical gel that is applied using a finger cot to the hairless skin inside a cat's ear. Many cat owners find this gel a good option for cats that don't like being given pills.[citation needed]

Radioiodine treatment, however, is not available in all areas, as this treatment requires nuclear radiological expertise and facilities that not only board the cat, but are specially equipped to manage the cat's urine, sweat, saliva, and stool, which are radioactive for several days after the treatment, usually for a total of 3 weeks (the cat spends the first week in total isolation and the next two weeks in close confinement).[67] In the United States, the guidelines for radiation levels vary from state to state; some states such as Massachusetts allow hospitalization for as little as two days before the animal is sent home with care instructions.[citation needed]

Dogs

[edit]

Hyperthyroidism is much less common in dogs compared to cats.[68] Hyperthyroidism may be caused by a thyroid tumor. This may be a thyroid carcinoma. About 90% of carcinomas are very aggressive; they invade the surrounding tissues and metastasize (spread) to other tissues, particularly the lungs. This has a poor prognosis. Surgery to remove the tumor is often very difficult due to metastasis into arteries, the esophagus, or the windpipe. It may be possible to reduce the size of the tumor, thus relieving symptoms and allowing time for other treatments to work.[citation needed] About 10% of thyroid tumors are benign; these often cause few symptoms.[citation needed]

In dogs treated for hypothyroidism (lack of thyroid hormone), iatrogenic hyperthyroidism may occur as a result of an overdose of the thyroid hormone replacement medication, levothyroxine; in this case, treatment involves reducing the dose of levothyroxine.[69][70] Dogs which display coprophagy, the consumption of feces, and also live in a household with a dog receiving levothyroxine treatment, may develop hyperthyroidism if they frequently eat the feces from the dog receiving levothyroxine treatment.[71]

Hyperthyroidism may occur if a dog eats an excessive amount of thyroid gland tissue. This has occurred in dogs fed commercial dog food.[72]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Hyperthyroidism is a common endocrine disorder in which the gland produces excessive amounts of , primarily thyroxine (T4) and (T3), leading to an acceleration of the body's metabolic processes and affecting nearly every . This overproduction, also known as an overactive , disrupts normal regulation of , body temperature, digestion, and energy use, resulting in a hypermetabolic state that can cause significant morbidity if untreated. The condition is classified as overt hyperthyroidism when (TSH) levels are low or suppressed alongside elevated T4 and T3, or subclinical when TSH is low but T4 and T3 remain normal. The most prevalent cause worldwide is , an autoimmune condition where antibodies stimulate the to overproduce hormones, accounting for approximately 50-80% of cases in iodine-sufficient regions like the United States. Other key etiologies include and , where autonomous nodules in the gland independently secrete hormones, particularly in older adults or iodine-deficient areas. , an inflammation of the often triggered by viral infections, postpartum changes, or medications like , can also release stored hormones temporarily. Less common triggers involve excessive iodine intake, which overwhelms the gland's regulatory mechanisms, or rare pituitary tumors secreting excess TSH. Risk factors include female sex (affecting women up to 10 times more than men), age over 60, family history of thyroid disorders, recent , and , which exacerbates . Globally, hyperthyroidism impacts about 1-2% of the population, with subclinical forms being more prevalent than overt cases. Symptoms typically develop gradually and include unintentional despite increased appetite, or irregular heartbeat, nervousness, , tremors, excessive sweating, , , , and menstrual irregularities in women. In , patients may also experience eye problems such as bulging eyes () or skin changes like . Older adults might present atypically with , depression, or unexplained rather than classic hypermetabolic signs. Diagnosis involves blood tests measuring TSH, free T4, and T3 levels, often supplemented by thyroid scans or tests to identify the underlying cause. Untreated hyperthyroidism raises risks for serious complications, including , due to accelerated bone turnover, and, in rare cases, —a life-threatening surge of hormones with high mortality. Treatment options are tailored to the cause, severity, and patient factors, encompassing antithyroid drugs like methimazole to inhibit hormone synthesis, beta-blockers for symptom relief, radioactive iodine ablation to destroy overactive thyroid tissue, or surgical in select cases. Early intervention is crucial to prevent long-term cardiovascular and skeletal damage.

Overview

Definition and Classification

Hyperthyroidism is defined as a condition characterized by excessive production of by the itself, resulting in elevated circulating levels of thyroxine (T4) and/or (T3). This overproduction leads to thyrotoxicosis, the clinical syndrome of thyroid hormone excess that manifests as a hypermetabolic state affecting multiple organ systems. In contrast, thyrotoxicosis can occur independently of hyperthyroidism when excess are derived from exogenous sources, such as factitious thyrotoxicosis caused by surreptitious ingestion of thyroid hormone medications, or from the release of preformed hormones in conditions like , where the is inflamed and damaged rather than overactive. Thyroid hormones T3 and T4 play essential roles in regulating , protein synthesis, and , influencing nearly every tissue in the body. Under normal conditions, thyroid function is tightly controlled by the hypothalamic-pituitary-thyroid (HPT) axis: (TRH) from the stimulates the to secrete (TSH), which in turn prompts the gland to synthesize and release T4 and T3; elevated thyroid hormone levels exert on the and pituitary to suppress further TRH and TSH secretion. Hyperthyroidism is classified in several ways to guide and . Based on origin, it is primarily thyroidal (primary hyperthyroidism), arising from intrinsic dysfunction, or rarely central (secondary or tertiary), due to inappropriate TSH secretion from pituitary adenomas or hypothalamic disorders, respectively. By severity, it is categorized as overt hyperthyroidism, marked by suppressed TSH levels alongside elevated free T4 and/or T3, or subclinical hyperthyroidism, featuring low TSH with normal levels, which may be asymptomatic or produce milder effects like subtle . Etiologically, common forms include autoimmune causes such as , autonomous nodules like , and iodine-induced cases such as the , where excess iodine exposure triggers hyperthyroidism in iodine-deficient individuals with underlying nodular .

Pathophysiology

Hyperthyroidism arises from excessive production or release of , primarily thyroxine (T4) and (T3), disrupting the normal hypothalamic-pituitary-thyroid axis. This excess can result from increased synthesis, often driven by stimulation of the (TSH) receptor; accelerated release of preformed hormones due to glandular destruction. In the feedback loop, elevated free T4 and T3 levels suppress TSH secretion via on the pituitary and , typically leading to low or undetectable TSH in overt hyperthyroidism, as described by the relationship TSH ∝ 1 / (T3 + T4) in simplified terms, where hormone levels inversely regulate pituitary output. At the cellular level, thyroid hormone synthesis begins with iodide uptake into thyrocytes via the sodium-iodide symporter (NIS), powered by the sodium-potassium ATPase, followed by transport into the colloid by . Thyroid peroxidase (TPO) then oxidizes iodide to iodine using hydrogen peroxide and catalyzes its incorporation onto tyrosine residues in , forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). TPO further facilitates the coupling of these iodotyrosines—MIT with DIT to yield T3, or two DIT molecules to produce T4—before releases the hormones into circulation. Dysregulation, such as constitutive TSH receptor , amplifies these steps, leading to overproduction. Systemically, excess thyroid hormones bind nuclear receptors, upregulating genes that increase by enhancing Na+/K+-ATPase activity, thereby elevating oxygen consumption and heat production across tissues. This mimics beta-adrenergic stimulation, promoting , , and cardiovascular effects like increased , independent of catecholamines. Additionally, T3 stimulates activity via expression, accelerating and reducing bone mineral density. In specific etiologies, such as , TSH receptor-stimulating antibodies (TRAb) chronically activate the receptor, driving autonomous synthesis; toxic adenomas exhibit somatic TSH receptor mutations that confer nodular independence from TSH; and destructive processes in subacute or release stored hormones without new synthesis, causing transient excess.

Clinical Presentation

Signs and Symptoms

Hyperthyroidism typically presents with a range of symptoms resulting from excess thyroid hormone, affecting multiple organ systems and varying in severity based on the degree of hormonal elevation. Common general symptoms include , unintentional despite increased , , nervousness, , and menstrual irregularities in women. Cardiovascular manifestations are prominent and include , , widened , and, in advanced cases, due to increased metabolic demand. Neuromuscular symptoms often involve fine of the hands, proximal (), anxiety, irritability, , and , reflecting heightened sympathetic activity. Dermatological and gastrointestinal features encompass warm, moist skin, excessive sweating, thinning or brittle hair, , increased bowel frequency, and , which may be associated with malabsorption of certain nutrients, particularly fats (steatorrhea) and calcium, due to increased gastrointestinal motility, faster intestinal transit time, and reduced time available for absorption. Fat malabsorption is common, with fecal fat levels reaching up to 35 g/day in some cases, while calcium absorption is decreased; although glucose absorption may increase, overall rapid transit interferes with optimal nutrient absorption, stemming from accelerated and gastrointestinal motility. Hyperthyroidism may also be associated with lower urinary tract symptoms such as increased urinary frequency, polyuria, urgency, and nocturia. These symptoms, which can occasionally be presenting features, are generally mild and are thought to result from increased renal blood flow, elevated glomerular filtration rate, and altered renal water reabsorption. They typically improve or resolve with effective treatment of the underlying hyperthyroidism. In contrast, hypothyroidism is more commonly associated with reduced urinary frequency, urinary retention, and bladder atony. Ocular signs, generalizable across causes but more pronounced in , include and retraction, which may contribute to a staring appearance. A goiter, or enlarged , is present in the majority of cases, the most common etiology of hyperthyroidism, often appearing as diffuse neck swelling. In elderly patients, hyperthyroidism may manifest as apathetic hyperthyroidism, with subtler symptoms mimicking depression, such as weight loss, fatigue, apathy, and withdrawal, rather than classic hypermetabolic features. Symptom intensity generally correlates with elevated free T4 and T3 levels, though extreme exacerbations like represent acute beyond typical presentations.

Thyroid Storm

, also known as thyrotoxic crisis, is a rare but life-threatening endocrine emergency characterized by an acute exacerbation of hyperthyroidism, resulting from a sudden and excessive release of leading to multi-organ dysfunction. It typically occurs in patients with underlying hyperthyroidism, such as , and represents a decompensated state rather than a distinct entity. Common precipitants include infections (the most frequent trigger), (thyroid or non-thyroid), trauma, iodine-containing contrast media, discontinuation of antithyroid therapy, and other stressors like parturition or burns. Clinically, thyroid storm manifests with severe systemic symptoms, including high fever exceeding 102°F (38.9°C), often reaching 104–106°F (40–41.1°C); profound tachycardia greater than 140 beats per minute; and central nervous system alterations ranging from agitation and confusion to delirium or coma. Gastrointestinal involvement is prominent, featuring nausea, vomiting, diarrhea, and occasionally jaundice due to hepatic dysfunction, while cardiovascular complications such as atrial fibrillation, heart failure, or shock may arise. These features reflect a hypermetabolic crisis with heightened sympathetic activity. Diagnosis relies on clinical assessment, as laboratory confirmation of hyperthyroidism alone is insufficient; the Burch-Wartofsky Point Scale provides a standardized scoring system, assigning points for thermoregulatory dysfunction (e.g., 30 points for temperature >104°F), central nervous system effects (e.g., 30 for coma), gastrointestinal symptoms (e.g., 20 for severe ), and cardiovascular issues (e.g., 15 for severe congestive ), among others, with a score greater than 45 indicating high likelihood of and 25–44 suggesting imminent risk. Elevated free thyroxine (T4) and (T3) levels with suppressed support the diagnosis but are not specific to the storm. Pathophysiologically, thyroid storm arises from an abrupt surge in circulating , often triggered by increased release or reduced binding to proteins during acute illness, coupled with enhanced end-organ sensitivity that amplifies hyperactivity, mimicking catecholamine excess and leading to a hyperadrenergic state. This cascade promotes widespread tissue oxygen demand, potentially culminating in multi-organ failure, including hepatic congestion, cardiac arrhythmias, and acute respiratory distress. Despite prompt intervention, mortality from has decreased to approximately 1-6% with modern management as of 2025, primarily due to cardiovascular collapse or infection-related complications. Its incidence is estimated at approximately 1.4 cases per 100,000 persons per year in females and 0.7 per 100,000 in males, with higher rates among hospitalized patients.

Causes

Autoimmune Causes

Autoimmune causes of hyperthyroidism primarily involve dysregulated immune responses targeting the gland, leading to excessive hormone production or release. The most common etiology is , an organ-specific autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI or TRAb) that bind to and activate the (TSHR) on thyroid follicular cells, mimicking the action of (TSH) and causing diffuse glandular and hyperfunction. These autoantibodies stimulate cyclic AMP production, promoting thyroid hormone synthesis and secretion, which accounts for 60-80% of hyperthyroidism cases in iodine-sufficient regions worldwide. The pathogenesis of Graves' disease involves both humoral and cellular immunity, with B cells producing the pathogenic TRAb and T cells providing helper functions through release that amplify the autoimmune response. Genetic susceptibility plays a key role, with associations to (HLA) alleles such as HLA-DR3, which influences and T-cell activation in tissue. Environmental factors can trigger or exacerbate the disease in genetically predisposed individuals, including cigarette smoking, which increases risk by promoting and immune dysregulation; , potentially via neuroendocrine pathways; and excess iodine intake, which may enhance autoantigen presentation. Graves' disease exhibits a marked female predominance, with a female-to-male of 5-10:1, likely influenced by estrogen-mediated immune modulation. It is also associated with other autoimmune conditions, such as and , reflecting shared genetic and immunological pathways that heighten overall risk. In some cases, TSHR autoantibodies cross-react with orbital antigens, contributing to extrathyroidal manifestations like ophthalmopathy through shared immunogenic epitopes. Other autoimmune etiologies include transient hyperthyroid phases in conditions like and . Hashitoxicosis represents an initial destructive hyperthyroid state in , where antibody-mediated (anti-thyroid peroxidase or anti-thyroglobulin) inflammation causes follicular disruption and release of preformed thyroid hormones, typically resolving into . , occurring in 5-10% of women within the first year after delivery, involves a similar autoimmune destructive process driven by rebound T-cell and activity following pregnancy-induced immune suppression, often presenting with a hyperthyroid phase due to hormone leakage before progressing to in many cases. These conditions highlight the spectrum of autoimmune thyroiditis, where initial hyperthyroidism stems from glandular destruction rather than stimulation.

Non-Autoimmune Causes

Non-autoimmune causes of hyperthyroidism encompass structural abnormalities in the gland, inflammatory conditions leading to hormone release, and exogenous factors that disrupt normal function. These differ from autoimmune etiologies by lacking antibody-mediated stimulation, instead involving autonomous hormone production or leakage of pre-formed hormones. Toxic nodular goiter, also known as , arises from multiple autonomous nodules that independently produce excess , often appearing as "hot" areas on with suppressed uptake in surrounding tissue. This condition is more prevalent in iodine-deficient regions, where the incidence is 1.5-18 cases per 100,000 person-years, compared to lower rates in iodine-sufficient areas. It typically affects older adults and develops gradually from longstanding non-toxic goiter. Toxic adenoma refers to a single hyperfunctioning that autonomously secretes , accounting for approximately 5-10% of hyperthyroidism cases, particularly in iodine-deficient populations. These benign tumors suppress TSH levels and function independently of regulatory signals, leading to clinical hyperthyroidism without systemic . They are more common in women and often present as a palpable solitary nodule. Thyroiditis variants represent inflammatory processes that cause transient hyperthyroidism through destructive release of stored , rather than increased synthesis. , often viral in origin and associated with upper respiratory infections, presents with painful enlargement, fever, and elevated inflammatory markers; it affects women more frequently and resolves spontaneously in most cases. Silent thyroiditis, a painless form, involves lymphocytic infiltration and leakage, commonly seen postpartum but also in non-pregnant individuals without evident . Drug-induced , triggered by agents like or , disrupts follicular integrity; , for instance, can induce type 1 thyrotoxicosis via iodine excess in susceptible glands or type 2 through direct . Exogenous causes stem from external thyroid hormone or iodine overload, mimicking endogenous hyperthyroidism biochemically but with low or absent thyroidal radioiodine uptake. Iatrogenic hyperthyroidism results from excessive dosing in treatment, emphasizing the need for regular TSH monitoring to prevent overdose. Factitious hyperthyroidism, or thyrotoxicosis factitia, involves surreptitious ingestion of thyroid hormone preparations, often for or psychological reasons, and is characterized by suppressed levels. Iodine excess, from supplements, contrast agents, or medications like , can precipitate hyperthyroidism in predisposed individuals with underlying nodular disease, as high iodine loads overwhelm the gland's regulatory mechanisms. Rare non-autoimmune causes include , where markedly elevated (hCG) from molar pregnancies or choriocarcinomas cross-reacts with the TSH receptor, stimulating thyroid hormone production; this can occur in up to 20-50% of complete hydatidiform mole cases with hCG levels exceeding 100,000 IU/L. Rarely, TSH-secreting pituitary adenomas (TSHomas) cause central hyperthyroidism by autonomous TSH production, accounting for less than 1% of cases.

Diagnosis

Laboratory Tests

The diagnosis of hyperthyroidism begins with biochemical confirmation through , typically prompted by symptoms such as unexplained or . The primary screening test is serum (TSH), which is suppressed in hyperthyroidism due to from excess . A TSH level below 0.1 mU/L is highly suggestive of hyperthyroidism, particularly when accompanied by elevated free thyroxine (T4) or (T3). Overt hyperthyroidism is characterized by low TSH with elevated free T4 and/or total T3 levels, confirming excess thyroid hormone production. In hyperthyroidism involving increased hormone synthesis (e.g., Graves' disease or toxic nodular goiter), serum thyroglobulin (Tg) levels are typically elevated due to enhanced glandular stimulation and synthesis, alongside elevated T3 and T4 with suppressed TSH; this contrasts with lower Tg in destructive thyroiditis or exogenous causes. In subclinical hyperthyroidism, TSH is low or undetectable while free T4 and T3 remain within normal ranges, often representing an early or mild form of the condition. Some cases, particularly in , exhibit T3-predominant hyperthyroidism, where T3 levels are disproportionately elevated compared to T4. To identify the underlying , assays are essential. (TRAb), including thyroid-stimulating immunoglobulins (TSI), are positive in over 90% of cases and confirm autoimmune stimulation of the . In contrast, anti- peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) may be elevated in destructive , indicating autoimmune-mediated damage rather than overproduction. Ancillary laboratory tests provide supportive evidence and assess complications. A complete blood count (CBC) often reveals mild due to increased turnover, while with a left shift may occur in , a severe manifestation of hyperthyroidism. Liver enzymes, such as (ALT) and aspartate aminotransferase (AST), are frequently elevated in 15-76% of untreated cases, reflecting direct effects of excess on hepatic function. Hypercalcemia, resulting from accelerated turnover and resorption, is observed in up to 20% of patients and can contribute to symptoms like . In amiodarone-induced hyperthyroidism, measurement of reverse T3 (rT3) is useful; elevated rT3 levels with high T4 but relatively low T3 help distinguish type 2 (destructive thyroiditis-like) from type 1 (iodine-induced overproduction). These tests collectively guide differentiation from other causes, with further imaging reserved for etiological confirmation.

Imaging and Other Studies

Thyroid scintigraphy serves as a primary imaging modality for evaluating the etiology of hyperthyroidism by assessing gland function and structure through the administration of radiotracers such as (123I) or pertechnetate (99mTc-pertechnetate). In , this test typically reveals diffusely increased radioiodine uptake, often exceeding 30% at 24 hours, reflecting enhanced activity, whereas uptake is low or suppressed in destructive due to impaired hormone synthesis. The scan also distinguishes hyperfunctioning "hot" nodules, indicative of toxic adenomas, from non-functioning "cold" nodules that may warrant further evaluation for . Additionally, whole-body scintigraphy can detect ectopic tissue, such as in , contributing to hyperthyroidism in rare cases. Ultrasound provides detailed anatomical assessment of the , particularly useful for characterizing nodules and evaluating parenchymal changes in hyperthyroidism. In , color often demonstrates markedly increased intrathyroidal vascularity, known as the "thyroid inferno" pattern, which correlates with disease activity. For nodular hyperthyroidism, the Thyroid Imaging Reporting and Data System (TIRADS) scoring system stratifies nodules based on ultrasound features like composition, , margins, calcifications, and shape to estimate malignancy risk and guide decisions. Computed tomography (CT) or (MRI) is employed when evaluating large goiters or retrosternal extension, providing critical information on tracheal compression, vascular involvement, and surgical planning. These modalities are particularly valuable in cases where is limited by anatomy or when assessing compressive symptoms. (PET), typically with 18F-fluorodeoxyglucose (FDG), is rarely indicated but may be used in suspected thyroid malignancy or to evaluate incidentalomas detected on other imaging. Functional tests like (TRH) stimulation, which provoke a blunted or absent (TSH) response in overt hyperthyroidism, have largely been supplanted by more sensitive laboratory assays and are now rarely performed.

Subclinical Hyperthyroidism

Subclinical hyperthyroidism is defined as a persistently suppressed serum (TSH) level, typically below 0.1 mU/L, accompanied by normal levels of free thyroxine (T4) and (T3). This condition reflects mild thyroid hormone excess without overt clinical symptoms, distinguishing it from manifest hyperthyroidism. Its prevalence in the general population ranges from 0.5% to 2%, with higher rates observed in older adults and regions with . In the United States, subclinical hyperthyroidism affects approximately 0.7% to 1.4% of individuals overall, rising to 1% to 8% among those over 65 years. The condition carries several health risks, particularly in vulnerable populations. It is associated with a 2- to 3-fold increased risk of , especially when TSH is below 0.1 mU/L and in patients over 60 years, contributing to higher rates of cardiovascular events such as coronary heart disease and . health is also affected, with accelerated bone loss and a higher incidence of and fractures in postmenopausal women. Additionally, subclinical hyperthyroidism has been linked to cognitive decline, reduced , and increased overall mortality, though these associations are more pronounced with prolonged duration and lower TSH levels. Recent data emphasize that cardiovascular risks escalate significantly with TSH suppression below 0.1 mU/L, independent of other factors. Progression to overt hyperthyroidism occurs at a rate of 2% to 5% per year on average, though this can reach up to 7% annually in cases with very low TSH or underlying , and is higher among the elderly. Conversely, spontaneous normalization of TSH levels happens in up to 12% of cases per year. Routine screening for subclinical hyperthyroidism is not recommended by major guidelines, including for high-risk groups such as individuals over years; however, if detected through testing prompted by symptoms or other indications, evaluation and management are advised. Management focuses on risk stratification rather than universal treatment. Intervention with antithyroid medications or other therapies is recommended for patients over 65 years with TSH below 0.1 mU/L, or those with comorbidities such as , heart disease, or , to mitigate associated risks. For milder cases (TSH 0.1-0.4 mU/L) or younger patients without symptoms, periodic monitoring of TSH levels every 6 to 12 months is sufficient, with reassessment for progression or complications. This approach balances potential benefits against treatment side effects, guided by clinical guidelines from endocrine societies.

Treatment

Antithyroid Medications

Antithyroid medications (ATDs), also known as thionamides, represent a cornerstone of first-line pharmacological for hyperthyroidism, particularly in cases like , by reversibly inhibiting hormone synthesis to restore euthyroidism. These agents are preferred initially due to their non-ablative nature, allowing for potential remission without permanent ablation. The primary ATDs are methimazole (MMI), carbimazole (a prodrug converted to methimazole and commonly used in regions such as Europe and the UK), and (PTU). Methimazole or carbimazole is the preferred agent in most non-pregnant adults, with an initial dose of 10-30 mg daily for methimazole (or equivalent for carbimazole), titrated based on clinical response and . is recommended at 300-600 mg daily for severe hyperthyroidism or during the first trimester of , where it is favored over methimazole due to a lower risk of congenital anomalies. After the first trimester, switching to methimazole is often advised to minimize PTU-related risks. Both drugs exert their primary effect by inhibiting , the enzyme essential for iodination of residues and coupling to form thyroxine (T4) and (T3) within the gland. Uniquely, PTU also blocks peripheral deiodination of T4 to the more active T3 by inhibiting 5'-, providing an additional benefit in acute hyperthyroid states like . Treatment regimens for Graves' disease include dose titration to achieve normalization of (TSH) and free T4 levels, typically within 4-8 weeks, followed by dosing, or the block-and-replace regimen, which combines high-dose ATDs to block thyroid hormone production with levothyroxine replacement to maintain euthyroidism and may be used in cases of poor response to titration or high relapse risk. Therapy duration is generally 12-18 months, after which discontinuation is attempted; remission rates in range from 30-50%, with predictors including lower pretreatment TSH receptor antibody levels and smaller goiter size. Adverse effects necessitate vigilant monitoring. Agranulocytosis, a severe reduction in neutrophils, occurs in 0.2-0.5% of patients and requires immediate drug cessation upon symptoms like or fever; routine monitoring is recommended, especially in the first 3 months. Hepatotoxicity is more common with PTU than methimazole, potentially leading to in rare cases, prompting baseline and periodic . Pruritic affects up to 5% of users and often resolves with antihistamines or dose adjustment. Recent studies from 2023-2025 have explored prolonged ATD use beyond , demonstrating and higher sustained remission rates—up to 60% with extended —particularly in patients with fluctuating activity. Additionally, mathematical models integrating patient-specific have been developed to predict free T4 trajectories and optimize dosing, enhancing precision in achieving euthyroidism while minimizing side effects. For patients unsuitable for long-term ATD therapy, radioactive iodine serves as a definitive alternative, though it carries a risk of permanent hypothyroidism. Symptomatic relief with beta-blockers may complement ATDs during .

Radioactive Iodine Therapy

Radioactive iodine therapy, utilizing (¹³¹I), serves as a definitive treatment for hyperthyroidism by ablating overactive tissue. The procedure involves of ¹³¹I in the form of a capsule or liquid, which is selectively taken up by the sodium-iodide symporter in follicular cells. Once absorbed, the isotope emits beta particles that damage and destroy follicles, leading to reduced production over time. This non-invasive approach is typically performed on an outpatient basis, with patients advised to follow radiation safety precautions, such as limiting close contact with others for a few days to weeks post-treatment. Dosing strategies for ¹³¹I therapy include fixed doses, commonly 10-15 mCi (370-555 MBq), or calculated doses based on thyroid gland size, radioiodine uptake, and desired therapeutic outcome. The goal is often to induce in 80-90% of patients, as this ensures complete resolution of hyperthyroidism while allowing straightforward management with replacement. Fixed dosing is simpler and widely used for , while calculated approaches may be preferred for toxic nodules or multinodular goiter to minimize . Indications for radioactive iodine therapy primarily include and toxic thyroid nodules, where it provides a durable cure by permanently reducing thyroid function. It is contraindicated in , including for patients with Graves' disease, and due to the risk of fetal or infant thyroid damage, with pregnancy delayed for at least 6-12 months afterward. Pretreatment with antithyroid drugs may be used to deplete thyroid hormone stores and prevent symptom exacerbation during therapy. Common side effects include a transient flare of hyperthyroidism in 5-10% of patients, occurring shortly after administration due to initial release from damaged cells, as well as inevitable typically onsetting within 2-3 months. Other potential issues encompass inflammation () or dryness from radiation uptake in salivary tissues, and mild neck tenderness managed with analgesics. Long-term, patients require monitoring for , which develops in the majority and necessitates lifelong replacement. Outcomes demonstrate remission of hyperthyroidism in 80-90% of patients after a single dose, with full effects manifesting over 2-6 months. Recent trends favor radioactive iodine over surgical options for most eligible cases, with reserved for approximately 5-10% of patients due to its invasiveness. This therapy's efficacy and safety profile make it a cornerstone of definitive , though repeated doses may be needed in 10-20% of non-responders.

Surgical Interventions

Surgical interventions for hyperthyroidism primarily involve , a procedure that removes part or all of the gland to provide a definitive cure by eliminating the source of excess hormone production. This approach is particularly valuable when medical therapies fail or are contraindicated, offering rapid resolution of symptoms compared to other modalities. is typically performed under general through a transverse incision in the , with careful preservation of the recurrent laryngeal and parathyroid glands to minimize complications. The choice of procedure depends on the underlying cause of hyperthyroidism. For , the most common etiology, total or near-total thyroidectomy is recommended to remove nearly all thyroid tissue, reducing the risk of recurrent hyperthyroidism to less than 1%. In contrast, for a solitary toxic nodule, a —removal of the affected thyroid lobe along with the —may be sufficient, preserving the contralateral lobe to avoid . These operations are ideally conducted by high-volume surgeons, defined as those performing more than 30 thyroidectomies annually, to optimize outcomes. Indications for thyroidectomy include failure or intolerance to antithyroid medications, such as methimazole or ; large goiters causing compressive symptoms like or airway obstruction; suspicion of thyroid malignancy based on ; moderate-to-severe , where radioactive iodine is contraindicated; and patient preference for a swift, permanent resolution of hyperthyroidism. It is also favored in scenarios like with severe hyperthyroidism unresponsive to medications, as it avoids potential fetal risks from prolonged antithyroid drug exposure. Additionally, surgery is considered for young patients or those with contraindications to radioactive iodine, such as desire for future . Preoperative preparation is essential to mitigate risks, beginning with achieving a euthyroid state using antithyroid drugs (e.g., methimazole 10-40 mg daily) combined with beta-blockers (e.g., 10-40 mg three to four times daily) to control symptoms like and prevent ; this typically takes 6 weeks to 3 months. In the 7-10 days prior to surgery, —such as Lugol's solution (5-7 drops three times daily) or saturated solution of (1-2 drops three times daily)—is administered to decrease thyroid vascularity, thereby reducing intraoperative blood loss by up to 40%. Calcium and supplementation may also be given prophylactically to address potential . Antithyroid drugs are discontinued on the day of , while beta-blockers are continued and tapered postoperatively. Complications of thyroidectomy for hyperthyroidism, though generally low in experienced hands, are slightly elevated in due to the gland's increased and . The following table summarizes key complication rates from a large single-center study of 594 patients undergoing total for :
ComplicationTransient RatePermanent Rate
Recurrent laryngeal nerve palsy5.2%0.16%
()40.6%0.5%
(requiring intervention)-0.5%
-1.8%
Other risks include (less than 1%) and , which may necessitate evacuation in up to 1-3% of cases. Transient often resolves with oral calcium and , but permanent requires lifelong management. Following total or near-total , patients require lifelong replacement to maintain euthyroidism. Surgery accounts for approximately 10-30% of definitive treatments for in various cohorts, with higher utilization in cases of severe ophthalmopathy or , where it may be preferred over alternatives for its immediacy and safety profile in these populations. In pregnant patients with refractory hyperthyroidism, is often performed in the second trimester, achieving cure rates near 100% with low maternal and fetal risks when properly prepared.

Adjunctive and Symptomatic Management

Adjunctive therapies in hyperthyroidism primarily target symptom relief and support primary treatments by addressing adrenergic manifestations and accelerating hormone clearance. Beta-blockers, such as , are commonly employed to alleviate symptoms including , , , , and anxiety, providing rapid onset of action within minutes. , a nonselective beta-blocker, is preferred due to its ability to block peripheral conversion of T4 to T3 in addition to controlling and psychomotor symptoms; typical dosing ranges from 10-40 mg orally three to four times daily, adjusted to 80-320 mg/day based on response, with caution in patients with , COPD, or . Other symptomatic agents include cholestyramine, a that binds in the intestine, reducing serum levels by up to 30% when used as an adjunct in refractory cases. Dosing typically starts at 4 g orally twice daily, increasing to 4 g three times daily for a total of 12 g/day, leading to normalization of free T4 within 12 days in reported cases of iodine-induced hyperthyroidism. Glucocorticoids, such as , are utilized in specific scenarios like or severe thyrotoxicosis to inhibit T4-to-T3 conversion and provide anti-inflammatory effects, with dosing at 40 mg daily for 1-2 weeks followed by taper in . In thyroid storm, a life-threatening exacerbation of hyperthyroidism, management emphasizes supportive measures alongside pharmacotherapy. Supportive care involves cooling with ice packs or blankets, intravenous fluids (dextrose-containing), electrolyte correction, and intensive care monitoring to address hyperthermia, dehydration, and organ dysfunction. The protocol includes beta-blockade with at 60-80 mg orally every 4-6 hours or intravenous 0.5-1 mg boluses, antithyroid drugs like 200 mg every 4 hours followed by iodine (e.g., Lugol's solution 10 drops every 8 hours, delayed at least 1 hour after antithyroid initiation to block hormone release), and glucocorticoids such as 100 mg intravenously every 8 hours for adrenal support and conversion inhibition. Aspirin is avoided as it may displace from binding proteins, exacerbating the condition. Recent guidelines, including the 2016 American Thyroid Association recommendations, stress rapid loading of antithyroid drugs with these adjuncts for optimal outcomes in storm. Dietary modifications support overall by mitigating hormone production and protecting against complications like bone loss. Iodine restriction is advised in cases of excess intake to prevent worsening hyperthyroidism, limiting foods such as iodized salt, , and to under 50 mcg/day if preparing for therapies or in iodine-induced states. Stimulants like from , , and energy drinks should be avoided to reduce anxiety and . There is no clinical evidence supporting soy or isoflavones as a treatment for hyperthyroidism, including Graves' disease, as they show no reliable effects on lowering FT3/FT4 or raising TSH; management should rely on established therapies such as antithyroid drugs. Soy products may also interfere with radioactive iodine uptake. For bone health, given the risk of from prolonged hyperthyroidism, supplementation or intake of calcium (e.g., from , ) and (e.g., from fortified non-iodized cereals) is recommended, particularly in at-risk patients.

Emerging Therapies

Recent advances in the treatment of hyperthyroidism, particularly in , have focused on targeted immunotherapies aimed at modulating the underlying autoimmune response rather than solely suppressing thyroid hormone production, building on 2025 guidelines such as those from the Korean Thyroid Association that endorse extended low-dose ATD and fixed-dose radioactive iodine as bridges to novel options. Monoclonal antibodies such as rituximab, which depletes B-cells via anti-CD20 targeting, have shown remission rates of 40-48% in phase 2 trials among patients with low thyrotropin receptor antibody (TRAb) levels or younger demographics, offering a potential alternative for those intolerant to conventional antithyroid drugs. Similarly, teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor primarily approved for thyroid eye disease, has demonstrated secondary benefits on thyroid autoimmunity by significantly reducing thyroid-stimulating immunoglobulin (TSI) from 1.90 IU/L to 0.69 IU/L and TRAb from 3.10 IU/L to 0.60 IU/L in studies of , though effects on thyroid hormones like free T4 and total T3 were variable and not always significant. Biologic agents targeting autoantibody production, particularly FcRn inhibitors, represent a promising class in ongoing trials as of 2025. Batoclimab, a subcutaneous anti-FcRn monoclonal antibody, achieved a 76% response rate (normalization of T3 and T4 without increased antithyroid drug dosing) at week 12 in a phase 2 trial of patients with uncontrolled Graves' hyperthyroidism, with 80% maintaining normal thyroid function and approximately 47% achieving antithyroid drug-free remission at six months post-treatment. Pivotal phase 3 trials for a next-generation agent, IMVT-1402, began enrollment in late 2024 with topline data expected in 2027. Efgartigimod, another FcRn inhibitor, is in phase 3 evaluation primarily for thyroid eye disease but shows potential for broader autoimmune thyroid modulation by reducing pathogenic IgG autoantibodies, though specific hyperthyroidism remission data remain limited to preclinical and early orbital studies. Veligrotug (VRDN-001), an IGF-1R antagonist similar to teprotumumab, met all primary endpoints in phase 3 trials for active thyroid eye disease in 2025, with a Biologics License Application submitted to the FDA in November 2025; it has indirect implications for associated hyperthyroidism through autoantibody reduction, but dedicated hyperthyroidism trials are not yet reported. Non-invasive ablation techniques, such as high-intensity focused ultrasound (HIFU), are under investigation for managing hyperfunctioning thyroid nodules contributing to hyperthyroidism, providing an outpatient alternative to . Systematic reviews indicate HIFU achieves a 75.8% success rate for benign nodule reduction at 6 months, with average volume decreases of 48.55% at 6 months and 55.02% at 12 months, and minimal complications like transient voice changes. Emerging enhancements, including thyroid-targeted nano-bombs (PSAPI) that encapsulate and for improved precision, have shown in preclinical models a significant increase in necrotic area and reduced relapse rates to 41.3% compared to standard HIFU, with high and lowered post-treatment inflammation. Other investigational approaches include TSH receptor (TSHR) and concepts to directly address autoimmune . The monoclonal TSHR K1-70 demonstrated symptom improvement without major adverse events in a phase 1 trial, while small-molecule variants like ANTAG-3 remain preclinical but show thyroid hormone reduction in animal models. For , antigen-specific immunotherapies like ATX-GD-59 achieved 50% normalization of T3 levels in a phase 1 trial, and preclinical TSHR-targeted CAR-T cells have eliminated TRAb-producing B-cells in mouse models, highlighting potential for durable remission but requiring further human validation. These therapies collectively aim for faster, etiology-specific remission rates of 30-50% in early data, surpassing the approximately 30% long-term remission with standard antithyroid drugs in recent 2024-2025 reviews.

Complications and Prognosis

Long-Term Complications

Untreated or inadequately managed hyperthyroidism can lead to various long-term organ-specific complications, primarily affecting the cardiovascular, skeletal, and ocular systems, with additional risks to muscle and structures. These sequelae arise from the sustained effects of excess on tissue and function, and while treatment often mitigates risks, some persist depending on disease duration and patient factors. Cardiovascular complications are among the most significant, with occurring in 10-15% of patients and carrying a of persistence even after achieving euthyroidism, particularly if has been prolonged. Excess thyroid hormone induces through increased and contractility, which can progress to and chronic in advanced cases, with an associated 60% higher mortality if untreated. Particularly in elderly patients with preexisting heart failure and atrial fibrillation, untreated hyperthyroidism—including subclinical or asymptomatic forms—increases the risk of cardiac decompensation, arrhythmias, and cardiovascular mortality. Recent studies also link subclinical hyperthyroidism to a 20-80% increased incidence of cardiovascular morbidity and mortality, underscoring the need for early intervention. Skeletal effects manifest as accelerated and resorption, leading to and accelerated loss, particularly affecting postmenopausal women who face a higher risk. In addition to accelerated bone turnover, decreased calcium absorption due to malabsorption from increased gastrointestinal motility contributes to bone loss and risk of osteoporosis. This loss contributes to reduced and increased fragility, with rates elevated due to the imbalance in bone turnover. In patients with , ocular complications such as develop in 20-30% of cases, featuring proptosis and from orbital inflammation and extraocular muscle involvement. significantly exacerbates the incidence and progression of this condition, increasing the risk up to sevenfold and impairing treatment response. Other complications include a low risk (3-5%) of in thyroid nodules associated with hyperthyroidism, necessitating evaluation for hyperfunctioning nodules. Proximal is common, but progression to remains rare, with only a handful of reported cases linked to thyrotoxicosis. Following radioactive iodine therapy, post-treatment develops in most patients within the first year, requiring regular monitoring of thyroid function every 4-6 weeks to initiate replacement promptly.

Prognosis and Outcomes

The prognosis of hyperthyroidism is generally favorable with appropriate treatment, with most patients achieving control of symptoms and normalization of thyroid function, though the specific outcomes depend on the underlying cause, such as or toxic nodular goiter, and the chosen therapy. Remission rates with antithyroid drugs (ATDs) typically range from 30% to 50%, but relapse occurs in approximately 50% of cases after discontinuation of therapy. In contrast, radioactive iodine () therapy and surgical interventions offer near-complete cure rates for hyperthyroidism, approaching 90-100%, though they often result in requiring lifelong thyroid hormone replacement. Several factors influence the likelihood of successful remission, particularly with ATDs; younger age and smaller goiter size are associated with better outcomes, while significantly worsens the prognosis for associated by increasing disease severity and reducing treatment efficacy. Recent 2024 studies indicate that 80-90% of patients achieve euthyroid status at one year following therapy, though up to 90% of those undergoing ablation require lifelong replacement due to induced . Emerging data on updated remission rates with novel adjunctive therapies, such as targeted immunomodulators, suggest potential improvements over traditional ATDs, addressing previous gaps in long-term control. Overall mortality is low, less than 1% in treated patients, with accounting for the majority of fatalities when it occurs, though prompt intervention reduces its impact. Cardiovascular events represent the primary long-term risk, particularly in untreated or inadequately managed cases. Post-remission monitoring includes annual TSH assessments to detect early, along with evaluations in at-risk populations, such as postmenopausal women, to mitigate from prior hyperthyroid effects.

Special Populations

Pregnancy

Hyperthyroidism during pregnancy is uncommon, with an incidence of 0.1% to 0.4% among pregnant individuals. In the first trimester, mild hyperthyroidism-like changes are physiologically normal due to (hCG), which peaks around 8 to 10 weeks and weakly stimulates the gland via structural similarity to (TSH), suppressing TSH levels to 0.1 to 0.4 mU/L and mildly elevating free thyroxine (FT4) levels; these changes typically resolve by mid-pregnancy. Gestational transient thyrotoxicosis, affecting 1% to 3% of pregnancies and often linked to , must be distinguished from true hyperthyroid disease such as , as the former is self-limited and does not require antithyroid treatment. Untreated or poorly controlled , the most common cause of overt hyperthyroidism in (occurring in about 0.2% of cases), increases maternal risks including (up to twofold higher), , , , and . Fetal and neonatal risks include , , goiter, prematurity, and neonatal hyperthyroidism in 1% to 5% of cases, primarily due to transplacental passage of maternal thyroid-stimulating immunoglobulins (TRAb). Diagnosis involves clinical assessment, trimester-specific (suppressed TSH with elevated FT4 confirming overt disease), and TRAb measurement in the first trimester for those with known or suspected , with repeat testing at 18 to 22 weeks and 30 to 34 weeks if initially elevated to predict fetal . Radioactive iodine uptake scans and therapy are contraindicated due to fetal . Management prioritizes antithyroid drugs (ATDs), with (PTU) preferred in the first trimester due to lower teratogenic compared to methimazole (3% versus 5% rate), followed by a switch to methimazole in the second and third trimesters if needed; the lowest effective dose is used to maintain FT4 in the upper normal range, with TSH levels that may remain suppressed. Beta-blockers such as may be used cautiously and short-term for symptomatic relief of or tremors until ATDs take effect, avoiding long-term use due to potential fetal growth restriction. For severe cases unresponsive to ATDs or with allergies, is considered in the second trimester. The 2017 American Association (ATA) guidelines emphasize shared decision-making on ATD choice; liver function should be assessed if clinical suspicion of arises. Neonates of mothers with require monitoring for hyperthyroidism, particularly if maternal TRAb levels are high.

Other Animals

Hyperthyroidism is the most common endocrine disorder in cats, particularly affecting senior animals over 10 years of age, with a prevalence of approximately 10% in this population. In felines, the condition is primarily caused by adenomatous of the , leading to excessive production of . Clinical signs include progressive despite increased appetite, and , and potentially , which can manifest as heart murmurs or gallop rhythms. Among cats, the incidence ranges from 1% to 3%, with certain breeds such as Siamese showing a predisposition, possibly due to genetic factors influencing morphology. In dogs, hyperthyroidism is rare compared to cats, often resulting from in about 50% of cases or functional adenomas, with multinodular being less common than in felines. Signs are similar to those in cats, including , , and increased thirst, but dogs frequently present with palpable masses due to the more pronounced enlargement of the gland. Diagnosis in both species relies on measuring elevated total thyroxine (T4) levels in serum, often confirmed by using pertechnetate to visualize hyperfunctional tissue. Treatment options mirror those used in humans, such as methimazole to inhibit hormone synthesis, surgical , or radioactive iodine () therapy, which is particularly preferred in cats for its high efficacy and non-invasive nature, achieving cure rates of up to 95% with a single dose. Recent advancements in veterinary protocols, including optimized dosing based on 2023 studies on body weight and renal function, have improved outcomes by reducing incidence to under 15% post-treatment. Unlike in humans, where drives autoimmune hyperthyroidism, the condition in cats and dogs is predominantly nodular or neoplastic, highlighting etiological differences that influence therapeutic approaches.

Epidemiology and History

Epidemiology

Hyperthyroidism affects approximately 1-2% of the global population, with overt cases comprising about 0.5% and subclinical cases ranging from 0.7% to 1.7%. The condition is significantly more prevalent in women, with a female-to-male of 5-10:1, reflecting hormonal and genetic influences that predispose females to autoimmune thyroid disorders like , the leading cause. In the United States, the and Nutrition Examination Survey (NHANES III) estimated an overall prevalence of 1.3%, including 0.5% overt and 0.7% subclinical hyperthyroidism. The annual incidence of , the most common etiology, ranges from 20 to 50 cases per 100,000 population in iodine-sufficient regions. Incidence of toxic nodular goiter varies by iodine status, occurring at 3-6 cases per 100,000 per year in iodine-replete areas and rising to 20-40 cases per 100,000 in iodine-deficient regions.02016-0/fulltext) Recent data from 2024 indicate an increasing trend in hyperthyroidism incidence in iodine-sufficient populations, potentially linked to improved diagnostics and environmental factors. Key risk factors include advanced age, with prevalence doubling in individuals over 60 years compared to younger adults. Female sex amplifies susceptibility, while smoking doubles the odds of developing ( 2.5). Iodine excess in replete areas heightens risk for toxic nodules, and genetic factors contribute substantially, with family history conferring up to a 30% increased familial risk through estimated at 79% for . Geographically, toxic nodular goiter is more prevalent in iodine-deficient and , while overt hyperthyroidism prevalence is 0.75% in and 0.78% in . In the , NHANES data confirm a 1.2% overall prevalence. Ethnically, rates are higher among Asians and than in Caucasians. Post-2020 trends show rising subclinical cases, possibly influenced by COVID-19-related thyroid disruptions. Recent studies from 2023-2025 link hyperthyroidism to elevated cardiovascular risk, with prevalence up to 17.5% among acute patients.

History

The earliest descriptions of hyperthyroidism emerged in the early , with English physician Caleb Hillier Parry providing the first detailed account of exophthalmic goiter in a posthumously published work in 1825, based on clinical observations dating back to 1786.00769-7/fulltext) In 1835, Irish physician independently described the condition in a series of clinical lectures, highlighting the triad of goiter, , and in female patients, which he termed a "newly observed affection of the thyroid gland." Shortly thereafter, in 1840, German physician Carl Adolph von Basedow reported similar cases in Europe, emphasizing the systemic effects including eye protrusion and cardiac symptoms, leading to the eponym "Basedow's disease" on the continent.00769-7/fulltext) Key milestones in understanding hyperthyroidism followed in the early , including the isolation of thyroxine by American Edward Calvin Kendall at the on December 25, 1914, which confirmed the role of in metabolic regulation and paved the way for hormone-based therapies. Surgical interventions, such as subtotal thyroidectomy, had become the primary treatment by the late 1800s, refined by pioneers like Theodor Kocher, but carried high risks of mortality and complications until preoperative iodine preparation was introduced in the 1920s.00769-7/fulltext) The advent of medical therapies transformed management in the 1940s, with antithyroid drugs (ATDs) like derivatives discovered through wartime research on sulfur compounds, enabling non-surgical control of thyroid overactivity and gaining widespread adoption post-World War II in the late 1940s and 1950s. A pivotal advancement was radioactive iodine (RAI) therapy, pioneered by American endocrinologist Saul Hertz, who administered the first therapeutic dose to a patient with in 1941, leveraging iodine's selective uptake by the to ablate overactive tissue—a method that became standard in the . In the 1970s, the discovery of thyroid receptor antibodies (TRAb), particularly thyroid-stimulating immunoglobulins (TSI), provided insight into the autoimmune basis of the disease, with studies in 1974 demonstrating that Graves' IgG competed with TSH for receptor binding, shifting paradigms toward immune-targeted diagnostics. The evolution of hyperthyroidism treatment has progressed from predominantly surgical approaches in the late 19th and early 20th centuries, which addressed goiter but not underlying , to multifaceted medical options by mid-century, including ATDs for reversible control and for definitive ablation.00769-7/fulltext) This shift reduced operative risks and improved outcomes, though early applications highlighted gaps in trial ethics, such as inadequate follow-up on effects.

References

Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.